Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species

Tracy L. Deem and Joan M. Cook-Mills

Lymphocytes bound at endothelial cell junctions extravasate within minutes. Lymphocyte-endothelial cell binding is mediated by receptors such as vascular cell adhesion molecule 1 (VCAM-1). VCAM-1 activates endothelial cell nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in minutes, and this activity is required for VCAM-1–dependent lymphocyte migration. In this report, we examined mechanisms for activation of matrix metalloproteinases (MMPs) during VCAM-1–dependent lymphocyte migration. Lymphocyte binding to VCAM-1 rapidly activated endothelial cell–associated MMPs. Furthermore, inhibition of MMPs on the endothelial cells but not on the lymphocytes blocked VCAM-1–dependent lymphocyte migration across endothelial cells. The activation of endothelial cell MMPs required VCAM-1–stimulated endothelial cell NADPH oxidase activity as determined by scavenging of reactive oxygen species (ROS) and by pharmacologic or antisense inhibition of NADPH oxidase. Exogenous addition of 1 μM H2O2, the level of H2O2 generated by VCAM-1–stimulated endothelial cells, rapidly activated endothelial cell–associated MMPs. In contrast, activation of lymphocyte-associated MMPs was delayed by hours after binding to VCAM-1, and this activation was blocked by inhibition of endothelial cell ROS generation. There was also a delay in H2O2–induced decrease in lymphocyte–associated tissue inhibitors of metalloproteinases (TIMPs), resulting in an increase in MMP/TIMP ratio. In summary, this is the first report of a mechanism for ROS function in VCAM-1 activation of endothelial cell MMPs during VCAM-1–dependent lymphocyte migration. (Blood. 2004;104:2385-2393)

© 2004 by The American Society of Hematology

Introduction

Lymphocytes migrate out of the blood between endothelial cells and into tissues where the lymphocytes can interact with antigen. Endothelial cells bind lymphocytes through cell surface adhesion molecules. One of these adhesion molecules is vascular cell adhesion molecule 1 (VCAM-1). It is important to understand VCAM-1 signaling because it is involved in several diseases. For example, VCAM-1 is required for eosinophil infiltration into the lung in experimental ovalbumin-induced asthma, as well as T-cell infiltration across the blood-brain barrier in experimental allergic encephalomyelitis (EAE). In addition, VCAM-1 functions in infiltration across the blood-brain barrier in experimental allergic encephalomyelitis (EAE). In addition, VCAM-1 functions in infiltration across the blood-brain barrier in experimental allergic encephalomyelitis (EAE). These ROS are required for VCAM-1–dependent lymphocyte migration. In this report, we demonstrate that VCAM-1 rapidly activates endothelial cell–dependent lymphocyte migration. Stimula
tion of VCAM-1 activates endothelial cell nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which catalyzes the release of low levels of reactive oxygen species (ROS) in cytokine-treated human umbilical vein endothelial cells (HUVECs) and in endothelial cell lines. These ROS are required for VCAM-1–stimulated endothelial cell actin restructuring and lymphocyte migration. Therefore, ROS are involved in modulating endothelial cell function to promote VCAM-1–dependent lymphocyte migration.

It has been reported that VCAM-1–dependent adhesion of a T-cell line activates lymphocyte matrix metalloproteinases (MMPs) after 5 hours. However, the mechanism(s) for VCAM-1 activation of lymphocyte MMPs is not known. It is also not known whether VCAM-1 signaling activates endothelial cell MMPs. Activated MMPs degrade extracellular matrix, cell surface receptors in cell-cell junctions, and tight junction proteins. MMP activation can be regulated by ROS. In smooth muscle cells, the latent form of MMP-2 (pro-MMP-2) is released after mechanical stretch-stimulated production of ROS by NADPH oxidase. In cell-free systems, low concentrations of ROS can activate pro-MMPs by oxidation of the sulfide bond in the prodomain of the MMP followed by release of this prodomain by autocatalytic cleavage. In this report, we demonstrate that VCAM-1 rapidly activates endothelial cell–associated MMPs and that this activation is mediated by endothelial cell–derived ROS. In addition, endothelial cell–derived ROS are involved in VCAM-1–stimulated activation of lymphocyte MMPs, and this lymphocyte MMP activation is delayed by several hours.

Materials and methods

Cells

The endothelial cell line mHEVc was previously derived from BALB/c mouse cervical lymph nodes and cultured as previously described. HUVECs obtained from Clonetics (Walkersville, MD) were grown in endothelial growth medium (Clonetics) plus 5% fetal calf serum (FCS) and
were used at passage 4 to 6. Mouse BALB/c CL.7 fibroblasts, obtained from American Type Culture Collection (Manassas, VA), were grown in Dulbecco modified Eagle medium (DMEM) plus 10% FCS. Single cell suspensions of spleen cells were prepared from freshly isolated spleens of male 6- to 8-week-old BALB/c mice (Harlan Industries, Indianapolis, IN) as previously described. Where indicated, red blood cells were lysed by hypotonic shock as previously described. Cell viability was determined by trypan blue exclusion.

**Antibody-coated beads**

Streptavidin-coated 9.9-μm diameter beads (40 Streptavidin-coated 9.9-μm diameter beads) were incubated with 6 μg biotin-conjugated goat antirat immunoglobulin (no. 3050-08; Southern Biotech, Birmingham, AL) in 75 μL phosphate-buffered saline (PBS) with gentle rocking for 1 hour at 4°C and then washed 3 times. These beads were incubated with 8 μg rat antirat isotype fluorochrome-labeled standard control morpholinooligomer (5′-CCTCTTATCCTGACGTTTACAT-3′) or a carboxyfluorescein-labeled monoclonal antibody against VCAM-1 (clone R35-95; PharMingen, San Diego, CA) in 40 μL PBS with gentle rocking for 1 hour at 4°C, washed, and suspended in 40 μL PBS. For experiments with HUVECs, the streptavidin-conjugated beads were coated with 12 μg biotin-conjugated goat antirat immunoglobulin G1 (IgG1; no. 12062D, PharMingen) and 8 μg mouse antihuman VCAM-1 (clone C-20; Santa Cruz Biotechnology, Santa Cruz, CA).

**Transwell migration assay**

mHEVc cells were grown to confluence on Transwells with 12-μm pores (Costar, Cambridge, MA). Spleen cell migration was performed as previously described. The mHEVc cell monolayers block nonspecific accumulation of red blood cells in the lower Transwell chamber and block fluorescent isothiocyanate (FITC)-labeled beads from migrating through the endothelial cell line.3,20 GM6001, but not the solvent, blocked this VCAM-1 dependent migration (Figure 1B). Blocking antibodies for these adhesion molecules inhibit lymphocyte adhesion and lymphocyte migration across the endothelial cells.20 These endothelial cells do not express other known ligands for lymphocyte binding such as intercellular adhesion molecule 1 (ICAM-1), PECAM-1, and E-selectin as determined by immunofluorescence labeling or cDNA microarray analysis (data not shown). The mHEVc cells constitutively express VCAM-1, thus providing a model to investigate VCAM-1 signals without interference initiated by signals from other adhesion molecules or from signals for induction of VCAM-1 expression. MMPs are implicated in VCAM-1-dependent lymphocyte migration between microvascular endothelial cells derived from rat epididymal fat pads.8 However, whether endothelial cell MMPs play a role in promotion of lymphocyte migration is not known. We first determined whether blocking MMP activity inhibited VCAM-1-dependent lymphocyte migration across mHEVc cells. Confluent monolayers of mHEVc cells on Transwell membranes were pretreated for 30 minutes with the general MMP inhibitor GM6001 (10 μM; Chemicon, Temecula, CA) or the solvent dimethyl sulfoxide (DMSO; 0.1%), and then the number of accumulated spleen cells that had migrated by 24 hours was examined. Migration is dependent on VCAM-1 because anti–VCAM-1 antibodies, which block lymphocyte adhesion to the mHEVc cells, block lymphocyte migration.20 GM6001, but not the solvent, blocked this VCAM-1-dependent lymphocyte migration (Figure 1A). To determine whether MMPs on the endothelial cells or lymphocytes were required for lymphocyte migration, the mHEVc cells or spleen cells were pretreated for 30 minutes with 10 μM GM6001 and then washed 5 times. Pretreatment of the endothelial cells with GM6001 blocked lymphocyte migration (Figure 1B). GM6001 completely blocked VCAM-1 activation of endothelial cell MMP activity at 20 to 30 minutes (Figure 2E), whereas migration was reduced by 50% at 24 hours (Figure 1B), indicating that endothelial cell MMPs are important for lymphocyte migration. Pretreatment of lymphocytes with GM6001 did not block migration (Figure 1C). The pretreated lymphocytes were sufficiently washed because there was no inhibition when the medium from the last wash was added to nontreated lymphocytes (Figure 1C). Similarly, another MMP inhibitor BB3103 (0.5 μM; British Biotech Pharmaceuticals, Oxford, England) blocked lymphocyte migration (Figure 1A).

**Results**

**Endothelial cell matrix metalloproteinases are required for lymphocyte migration across an endothelial cell line**

Spleen lymphocyte migration across the endothelial cell line mHEVc is dependent on VCAM-1/α4-integrin binding because blocking antibodies for these adhesion molecules inhibit lymphocyte adhesion and lymphocyte migration across the endothelial cells.20 These endothelial cells do not express other known ligands for lymphocyte binding such as intercellular adhesion molecule 1 (ICAM-1), PECAM-1, and E-selectin as determined by immunofluorescence labeling or cDNA microarray analysis (data not shown). The mHEVc cells constitutively express VCAM-1, thus providing a model to investigate VCAM-1 signals without interference initiated by signals from other adhesion molecules or from signals for induction of VCAM-1 expression. MMPs are implicated in VCAM-1-dependent lymphocyte migration between microvascular endothelial cells derived from rat epididymal fat pads.8 However, whether endothelial cell MMPs play a role in promotion of lymphocyte migration is not known. We first determined whether blocking MMP activity inhibited VCAM-1-dependent lymphocyte migration across mHEVc cells. Confluent monolayers of mHEVc cells on Transwell membranes were pretreated for 30 minutes with the general MMP inhibitor GM6001 (10 μM; Chemicon, Temecula, CA) or the solvent dimethyl sulfoxide (DMSO; 0.1%), and then the number of accumulated spleen cells that had migrated by 24 hours was examined. Migration is dependent on VCAM-1 because anti–VCAM-1 antibodies, which block lymphocyte adhesion to the mHEVc cells, block lymphocyte migration.20 GM6001, but not the solvent, blocked this VCAM-1-dependent lymphocyte migration (Figure 1A). To determine whether MMPs on the endothelial cells or lymphocytes were required for lymphocyte migration, the mHEVc cells or spleen cells were pretreated for 30 minutes with 10 μM GM6001 and then washed 5 times. Pretreatment of the endothelial cells with GM6001 blocked lymphocyte migration (Figure 1B). GM6001 completely blocked VCAM-1 activation of endothelial cell MMP activity at 20 to 30 minutes (Figure 2E), whereas migration was reduced by 50% at 24 hours (Figure 1B), indicating that endothelial cell MMPs are important for lymphocyte migration. Pretreatment of lymphocytes with GM6001 did not block migration (Figure 1C). The pretreated lymphocytes were sufficiently washed because there was no inhibition when the medium from the last wash was added to nontreated lymphocytes (Figure 1C). Similarly, another MMP inhibitor BB3103 (0.5 μM; British Biotech Pharmaceuticals, Oxford, England) blocked lymphocyte migration (Figure 1A).
Lymphocyte migration in vivo occurs primarily in postcapillary venules where shear stress is 2 dynes/cm². Therefore, we determined whether laminar flow modulated lymphocyte migration. In addition, migration is detected within minutes in this assay because the accumulation of fewer migrated cells is needed to detect migration with this assay than the Transwell assay. The measurements were performed in monolayers of mHEVc cells on glass slides treated with 10 μM GM6001, 50 μM MMP-2/MMP-9 inhibitor II set (Calbiochem), or the vehicle control, 0.1% DMSO, for 30 minutes and then washed. Resting splenic lymphocytes were added, and 2 dynes/cm² laminar shear stress was applied for 30 minutes. The cells were washed and fixed with 3% paraformaldehyde, and lymphocyte migration was examined by phase contrast microscopy (micrograph). The image was acquired using an Olympus BH-2 microscope (SPlan 40× objective lens with 0.7 aperture and a 3.3× internal lens) equipped with an Olympus C-35AD-2 camera. The micrograph was digitized using a Nikon SLC D1X digital camera and Adobe Photoshop 7.0. Nonmigrated lymphocytes are phase light (open arrow). In contrast, migrated lymphocytes appear as phase dark (closed arrow). Bar, 15 μm. GM6001 and BB3103 had no effect on cell viability, as determined by trypan blue exclusion (data not shown). Spleen lymphocytes were treated with 10 μM GM6001, and then the inhibitor was left in or GM6001-treated mHEVc cells were washed 5 times to remove excess inhibitor. (A-C) Spleen cells were added on top of the mHEVc monolayer. At 24 hours, cells were collected from the bottom chamber and counted. (A) Confluent monolayers of mHEVc cells in 12-μm pore Transwells were treated for 30 minutes with GM6001 or BB3103, general MMP inhibitors, or the solvent control, 0.1% DMSO. (B) mHEVc cells were treated for 30 minutes with 10 μM GM6001, and then the inhibitor was left in or GM6001-treated mHEVc cells were washed 5 times to remove excess inhibitor. (C) Spleen cells were treated with 10 μM GM6001 for 30 minutes and then washed 5 times to remove the inhibitor. For pretreated lymphocytes that were not washed, the final concentration of GM6001 in the coculture was 5 μM. In addition, medium from the last wash was added to nontreated spleen cells to ensure that the inhibitor was sufficiently removed. (A-C) Spleen cells were treated with 10 μM GM6001 and then the inhibitor was left in or GM6001-treated mHEVc cells were washed 5 times to remove excess inhibitor. Spleen lymphocytes were treated with 10 μM GM6001, and then the inhibitor was left in or GM6001-treated mHEVc cells were washed 5 times to remove excess inhibitor. Spleen lymphocytes were treated with 10 μM GM6001, and then the inhibitor was left in or GM6001-treated mHEVc cells were washed 5 times to remove excess inhibitor. Spleen lymphocytes were treated with 10 μM GM6001, and then the inhibitor was left in or GM6001-treated mHEVc cells were washed 5 times to remove excess inhibitor.
released MMPs are likely rapidly removed from the localized site of lymphocyte-endothelial cell contact by the flow of blood. Lymphocyte stimulation of endothelial cell MMPs was not examined because, when lymphocytes were released from the endothelial cells with anti–VCAM-1 antibodies, there were significant numbers of lymphocytes with cell-associated MMPs remaining in the endothelial cell preparation. Therefore, to address activation of endothelial cell–associated MMPs, endothelial cell VCAM-1 was stimulated by cross-linking with anti–VCAM-1 antibody-coated beads (9.9 μm in diameter). Anti–VCAM-1–coated beads also provided stimulation of VCAM-1 without complications of signals from subsequent cell-cell interactions. We have previously reported that lymphocytes as well as anti–VCAM-1–antibody-coated beads bind to VCAM-1 and activate NADPH oxidase in the mHEVc cells and in cytokine-treated primary cultures of HUVECs. Furthermore, this indicates that VCAM-1, rather than VCAM-1 cross talk with other cell surface molecules, is sufficient for the signals examined. Beads coated with anti-CD44, which is expressed by the mHEVc cells, have no effect on NADPH oxidase activation. mHEVc cells were stimulated with anti–VCAM-1 beads, washed, lysed, and examined by zymography. At 15 to 25 minutes, the anti–VCAM-1 antibody-coated beads significantly increased 2-fold the active form of MMP-2 and MMP-9 that was associated with the mHEVc cells (Figure 2A,E and Figure 3). MMP-2 and MMP-9 expression were identified by Western blot (Figure 2G) and by comparison to purified MMP standards in zymograms (data not shown). The mHEVc cells also express transmembrane MT1-MMP (Figure 2G), which has little gelatinase activity as determined by zymography, but importantly, it holds both pro–MMP-2 and active MMP-2 at the cell surface. incubation of the gel with EDTA blocked the enzymatic activity of MMP-2 and MMP-9, confirming cation dependence of the MMP activities (Figure 2C). VCAM-1 activation of MMPs was also examined in primary cultures of endothelial cells. Interleukin 4 (IL-4)–treated HUVECs expressed VCAM-1 (data not shown), and these cells expressed MMP-2 and MT1-MMP but not MMP-9 (Figure 2G). This is consistent with other reports that HUVECs primarily express MMP-2. Cross-linking VCAM-1 induced a significant increase in the active form of MMP-2 on HUVECs by 25 minutes (Figure 2B,F). In summary, within minutes, VCAM-1 stimulates MMP activation on endothelial cell lines and primary endothelial cells. This MMP activity is necessary for VCAM-1–dependent migration of lymphocytes across the endothelial cell lines.

VCAM-1 activation of endothelial cell MMPs is mediated by endothelial cell NADPH oxidase-generated ROS

VCAM-1 activates endothelial cell generation of 1 μM H2O2. The VCAM-1–stimulated ROS are generated from endothelial cell NADPH oxidase but not nitric oxide synthase, xanthine oxidase, or cytochrome P450. NADPH oxidase catalyzes the synthesis of superoxide, which dismutates to H2O2. This ROS generation is necessary for VCAM-1–dependent lymphocyte migration, and endothelial cell MMPs are involved in VCAM-1–dependent lymphocyte migration (Figure 1). Furthermore, it has been reported that low levels of H2O2 activate purified MMP-2 and MMP-9. Therefore, it was determined whether ROS generated by VCAM-1–stimulated endothelial cell NADPH oxidase activates endothelial cell–associated MMPs. To address this, mHEVc cells were pre-treated for 30 minutes with apocynin (4 mM), an NADPH oxidase inhibitor, or with catalase (5000 U/mL), a H2O2 scavenger. We have previously reported that these concentrations of apocynin and catalase block mHEVc cell VCAM-1–stimulated generation of ROS and block VCAM-1–dependent lymphocyte migration. Apocynin and catalase did not alter VCAM-1 expression on the endothelial cells as determined by flow cytometry (data not shown). The inhibitors did not affect endothelial cell viability as determined by trypan blue exclusion (data not shown). Anti–VCAM-1 bead activation of endothelial cell MMP-2 and MMP-9 activity was inhibited by apocynin and catalase (Figure 3). To further examine endothelial cell NADPH oxidase as an intermediate in VCAM-1 activation of MMPs, the mHEVc cells were transfected with a carboxyfluorescein-tagged morpholino-antisense to gp91 phox or carboxyfluorescein-tagged control morpholino oligomer and then cultured for 3 days. gp91 phox is the catalytic subunit of the NADPH oxidase enzyme complex. The mHEVc cells were successfully transfected (80%–90% transfection) as determined by flow cytometry (Figure 4A), and gp91 phox protein expression at 72 hours was inhibited more than 90% as determined by densitometry analysis of Western blots (Figure 4B). We previously reported that this gp91 phox morpholino antisense inhibits VCAM-1 activation of endothelial cell ROS production. VCAM-1 activation of MMP-2 and MMP-9 was blocked in cells transfected with the gp91 phox morpholino antisense as compared with control morpholino-treated cells (Figure 4 C-D). Therefore, endothelial cell NADPH oxidase was required for VCAM-1 induction of endothelial cell MMPs. In summary, ROS from VCAM-1–activated endothelial cell NADPH oxidase stimulates endothelial cell MMP activity, and this MMP activity in turn is required for endothelial cell promotion of VCAM-1–dependent lymphocyte migration.

Figure 3. An inhibitor of NADPH oxidase and a ROS scavenger block VCAM-1 activation of endothelial cell MMP-2 and MMP-9. (A,C) MMP-9 activity. (B,D) MMP-2 activity. mHEVc cells were incubated with anti–VCAM-1 antibody-coated beads in the presence and absence of apocynin (4 mM), an NADPH oxidase inhibitor, or catalase (5000 U/mL), a H2O2 scavenger. Apocynin and catalase had no effect on endothelial cell viability as determined by trypan blue exclusion (data not shown). At the times indicated the cells were washed, and equal cell numbers were lysed and analyzed by zymography as described for Figure 2. Data presented are the mean ± SD from 5 experiments. Symbols without error bars indicate that the SD was smaller than the symbol. *P < .05 compared with mHEVc cells at 0 minutes. **P < .05 compared with anti–VCAM-1–bead-stimulated cells.
Exogenous H$_2$O$_2$ activates endothelial cell–associated MMPs

In cell-free experiments, low concentrations of ROS activate purified MMP-2 and MMP-9, and high concentrations of ROS (> 50 µM) inhibit purified MMP activity. In cells, ROS can be generated extracellularly by the NADPH oxidase enzyme complex located in the endothelial cell plasma membrane. VCAM-1 stimulates the production of low levels of H$_2$O$_2$ by endothelial cells. Therefore, it was determined whether exogenous H$_2$O$_2$ at low levels could activate cell-associated MMPs. Low concentrations of H$_2$O$_2$ (1-10 µM) activated endothelial cell–associated MMP-2 and MMP-9 at 15 minutes (Figure 5). H$_2$O$_2$ (1 µM) did not alter expression of MMP-2, MMP-9, tissue inhibitor of metalloproteinase 1 (TIMP-1), or TIMP-2 at 15 minutes as determined by Western blot (data not shown), and there was very low TIMP expression by the endothelial cells as compared with lymphocytes, which is consistent with the literature. In contrast, 50 µM H$_2$O$_2$, a concentration produced by activated macrophages, inhibited endothelial cell MMP-2 and MMP-9 activity by 50% (Figure 5), which is consistent with previous reports that high levels of ROS inhibit cellular MMPs. Therefore, VCAM-1 activates endothelial cell NADPH oxidase for production of low concentrations of ROS that then can activate endothelial cell–associated MMPs.

VCAM-1 activation of endothelial cell MMP-2 and MMP-9 was not altered by laminar shear stress at 2 dynes/cm$^2$

Leukocyte transendothelial migration into inflammatory sites occurs primarily in postcapillary venules in which the laminar shear stress is 2 dynes/cm$^2$. Therefore, it was determined whether this shear stress modulated VCAM-1 activation of endothelial cell–associated MMPs. The mHEVc cells were grown on glass slides, attached to a parallel plate flow chamber, and then stimulated with anti–VCAM-1–coated beads under a laminar shear stress of 2 dynes/cm$^2$. This shear stress did not alter VCAM-1 activation of endothelial cell MMPs as compared with static conditions (Figure 6).

Lymphocyte MMP-9 activation is blocked by inhibition of endothelial cell NADPH oxidase

As ROS are released extracellularly and activate endothelial cell–associated MMPs, we determined whether these ROS also modulate MMP activity on the adherent lymphocytes. First, we examined activation of lymphocyte MMP activity after adhesion to mHEVc cells. Spleen lymphocytes were incubated with the mHEVc cells for 15 minutes and nonbound lymphocytes were washed, then equal cell numbers were lysed, and MMP activity was examined by zymography. H$_2$O$_2$ had no effect on cell viability (data not shown). Data presented are the mean ± SD from 3 experiments. *P < .05 compared with nonstimulated mHEVc cells.
removed, because at 15 minutes the maximal number of lymphocytes adhere to the endothelial cells. The bound lymphocytes and endothelial cells were incubated, and, at the time points indicated, lymphocyte binding was reversed with blocking anti–VCAM-1 antibodies. Lymphocyte-associated MMP activity was examined by zymography. Spleen lymphocyte MMP-9 activity was increased at 2 to 5 hours after addition to the mHEVc cells (Figure 7A), which is consistent with the more than 5 hours reported for VCAM-1 activation of lymphocyte MMPs. The less than 1% contaminating endothelial cells in this preparation did not contribute to the MMP activity observed for lymphocytes because, when this small number of remaining endothelial cells was obtained from a VCAM-1–stimulated monolayer and analyzed, there was no detectable endothelial cell MMP activity (data not shown). Thus, VCAM-1 stimulates a delayed activation of MMPs on lymphocytes as compared with the rapid activation of endothelial cell MMPs.

It was determined whether ROS mediate VCAM-1–stimulated activation of lymphocyte MMPs. mHEVc cells were pretreated with the NADPH oxidase inhibitor apocynin or the irreversible flavoprotein inhibitor diphenyliodonium, DPI, for 30 minutes prior to the addition of lymphocytes. DPI-treated cells were washed. Apocynin was left in the coculture because it is a reversible inhibitor. Lymphocytes were added to the endothelial cells, and, after 15 minutes nonadherent lymphocytes were removed. At 5 hours, anti–VCAM-1 antibody was added to release the bound lymphocytes. Lymphocyte MMP activity was examined by zymography as described in Figure 2. (A) mHEVc cells were pretreated with apocynin (4 mM) for 30 minutes. (C) mHEVc cells were pretreated with apocynin (4 mM) for 30 minutes and washed. Equal cell equivalents were examined by zymography as described in Figure 2. (B) Spleen cells were incubated with 1 μM H2O2 for 0, 0.25, or 5 hours. The 0.25- and 5-hour time points were chosen because they coincide with the time for the increased MMP activity on the endothelial cells and lymphocytes, respectively (Figures 3 and 7). Equal cell numbers were lysed, and expression of TIMP-1, TIMP-2, and MMP-9 was determined whether low levels of H2O2 such as those generated by VCAM-1 signaling could modulate MMP and TIMP expression in the resting splenic lymphocytes. Lymphocytes were incubated in the presence of 1 μM H2O2 for 0, 0.25, or 5 hours. The 0.25- and 5-hour time points were chosen because they coincide with the time for the increased MMP activity on the endothelial cells and lymphocytes, respectively (Figures 3 and 7). Equal cell numbers were lysed, and expression of TIMP-1, TIMP-2, and MMP-9 was analyzed by Western blot. H2O2 treatment did not increase lymphocyte MMP-9 expression (Figure 7G). In contrast, H2O2 induced a significant decrease in TIMP-1 and TIMP-2 protein expression at 5 hours. Apocynin blocked VCAM-1–stimulated lymphocyte MMP-9 activity (Figure 7C). DPI pretreatment of endothelial cells but not lymphocytes blocked VCAM-1 activation of lymphocyte MMPs (Figure 7D). Apocynin and DPI did not alter VCAM-1 expression or lymphocyte adhesion to the mHEVc cells. To determine whether extracellular ROS could activate lymphocyte-associated MMPs, exogenous H2O2 (1 μM) was added to spleen cells, and MMP was activity examined. Spleen cell MMP-9 was activated by 1 μM H2O2 but only after 2 to 5 hours (Figure 7B). Therefore, endothelial cell–derived ROS mediates a delayed activation of lymphocyte MMP-9 and a rapid activation of endothelial cell MMPs.

MMP activity is regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). It has been shown that leukocytes express high levels of TIMPs and a decrease in TIMP expression can yield a net increase in MMP activity. Therefore, it was determined whether low levels of H2O2 such as those generated by VCAM-1 signaling could modulate MMP and TIMP expression in the resting splenic lymphocytes. Lymphocytes were incubated in the presence of 1 μM H2O2 for 0, 0.25, or 5 hours. The 0.25- and 5-hour time points were chosen because they coincide with the time for the increased MMP activity on the endothelial cells and lymphocytes, respectively (Figures 3 and 7). Equal cell numbers were lysed, and expression of TIMP-1, TIMP-2, and MMP-9 was analyzed by Western blot. H2O2 treatment did not increase lymphocyte MMP-9 expression (Figure 7G). In contrast, H2O2 induced a significant decrease in TIMP-1 and TIMP-2 protein expression at 5 hours.
Discussion

We have shown for the first time that endothelial cell–associated MMP activity is increased within minutes after VCAM-1 cross-linking and that a mechanism for this activation is through endothelial cell NADPH oxidase-derived ROS. In addition, we demonstrated that endothelial cell–associated rather than lymphocyte–associated MMPs are necessary for VCAM-1–dependent lymphocyte migration across endothelial cells. VCAM-1 activation of NADPH oxidase and endothelial cell MMPs are required for VCAM-1–dependent lymphocyte migration because lymphocyte migration across mHEC cells is blocked by (1) antibody inhibition of VCAM-1 binding; (2) apocynin and DPI inhibition of endothelial cell NADPH oxidase activity but not inhibition of endothelial cell xanthine oxidase, nitric oxide synthase, or cytochrome P450; (3) scavenging of ROS by catalase or superoxide dismutase; and, as shown in this study, (4) inhibition of endothelial cell MMP activity. Endothelial cell MMP activity is downstream of VCAM-1 activation of NADPH oxidase because inhibition of NADPH oxidase or scavenging of ROS blocked VCAM-1 activation of endothelial cell MMP activity. These endothelial cell–generated ROS also mediate a delayed reduction in lymphocyte–associated TIMP expression and an increase in lymphocyte–associated MMP activity.

The level of H2O2 produced after VCAM-1 stimulation is approximately 1 μM, which is 50- to 200-fold lower than levels of H2O2 generated by macrophages and granulocytes.4 Most studies on ROS modulation of endothelial cell function focus on high levels of ROS for damage to endothelial cells.35 Furthermore, high levels of ROS induce changes in the entire endothelial cell with regard to actin fibers and tight junctions.35 In contrast, after VCAM-1 stimulation, low levels of ROS induce changes in endothelial cell actin structure only at the site of leukocyte adhesion.3,4 Two localized structural changes in endothelial cells are consistent with endothelial cell retraction at the site of lymphocyte migration while maintaining general vascular integrity. In further support for concentration-dependent mechanisms for ROS, high levels of exogenous ROS (≥50 μM) inhibit purified MMP activity, whereas less than 10 μM ROS activate purified MMPs.13 We demonstrated that these ROS concentrations had similar opposing effects on activation of endothelial cell–associated MMPs.

ROS are generated at the cell surface by NADPH oxidase, and MMPs are bound to the cell surface. MMP-9 is held at the cell surface by CD44.36 MMP-2 binds to MT1-MMP at the cell surface through a tertiary complex involving TIMP-2. The N-terminal end of the TIMP molecule binds to the N-terminal end of MT1-MMP, inhibiting the MT1-MMP catalytic site.37 This allows the free carboxy-terminal end of the TIMP molecule to bind to the carboxy terminal end of the MMP-2 molecule, leaving the N-terminal MMP-2 catalytic site uninhibited.37 MMP-2 can then be activated by a nearby MT1-MMP37 or in this model by ROS. Thus, low levels of TIMPs participate in holding active MMP-2 at the cell surface, whereas high levels of TIMPs block the active site of MMP-2.37

MMP function has been implicated in lymphocyte transendothelial migration.8 However, whether lymphocyte or endothelial cell MMPs were involved in this migration was not defined. Our studies using MMP inhibitors indicate that endothelial cell but not lymphocyte MMPs are required for VCAM-1–dependent lymphocyte migration between endothelial cells. The time for VCAM-1–stimulated ROS production and activation of endothelial cell MMPs is consistent with the time for transendothelial lymphocyte migration. Subsequent to binding to endothelial cells, most of the cells that are attached to endothelium then roll to bicuscular and tricellular endothelial cell junctions where they stop rolling and migrate between endothelial cells.38 Lymphocyte migration is an asynchronous process, but an individual lymphocyte, which had rolled to an endothelial cell junction, then migrates between the endothelial cells in less than 2 minutes.14 The maximal anti–VCAM-1–bead-stimulated endothelial cell MMP activity occurs in 15 minutes. These 15 minutes include the time for antibody-coated beads to settle asynchronously onto the endothelial cells and include the time for the antibodies to bind and activate VCAM-1. Therefore, the time for anti–VCAM-1–coated beads to stimulate endothelial cell MMP activity is similar in magnitude to the time for lymphocytes to migrate between the endothelial cells as compared with the several hour delay required for VCAM-1 activation of lymphocyte MMPs.

A role for ROS in activation of tumor cell MMPs has been reported. Antioxidants block an increase in pro-MMP secretion but not MMP mRNA by HL-60 leukemia cells at 3 days after butyric acid–induced cell differentiation.39 Overexpression of manganese superoxide dismutase, which scavenges superoxide, disrupts the ROS balance and increases MMP-2 secretion in MCF-7 breast cancer cells.40 The mechanism for the ROS modulation of MMPs in these tumor models was not defined. The VCAM-1–mediated activation of endothelial cell MMPs is likely a direct effect of ROS on MMPs because (1) activation occurred within minutes in our studies without altering MMP or TIMP expression and (2) low levels of exogenous H2O2 have been reported to directly activate purified MMPs.13,23 ROS oxidize the cysteine in the prodomain of MMPs, causing autocatalytic cleavage of the prodomain and activation of the MMP.33

In contrast to rapid endothelial cell MMP activation, MMP activity on lymphocytes is delayed by 2 hours after binding to VCAM-1 or after exogenous addition of 1 μM H2O2. Consistent with this finding, others have reported that T-cell MMP activation occurs 5 to 12 hours after adherence to endothelial cells or binding to ligands for α4-integrin.3,25,51 After adhesion, MMP-2 versus MMP-9 activation on T cells varies in the literature. Lymphocytes express MMP-9 with little to no MMP-225,42,49 unless under very restricted conditions.5,55,56 T cells that migrated across endothelial cells also exhibit increased MMP activity after 8 to 20 hours. However, the activation of T-cell MMPs by ligands such as fibronectin or VCAM-1 immobilized on plastic2,25,41 suggests that lymphocyte MMPs can be activated by “outside-in” signals from α4-integrins. Taken together with our studies, lymphocyte MMP activity can be activated by α4-integrin outside-in signals as well as through endothelial cell–derived ROS. The delayed activation of lymphocyte MMPs suggests that lymphocyte MMPs may participate in migration through extravascular tissue.

MMPs on endothelial cells are modulated by factors in the microenvironment such as the cytokine milieu.51 For example, large vein endothelial cells such as HUVECs express MMP-2 and little to no MMP-9, whereas microvascular endothelial cells, as shown in this study and others, express MMP-2 and MMP-9.52
However, even though MMP-9 is not expressed by IL-4–stimulated HUVECs, they can still promote lymphocyte migration. 25 This may be due to a redundancy in function of MMPs. Redundancy of MMP activity for neovascularization and hematopoietic stem cell mobilization was recently demonstrated in vivo by using MMP-9 knockout (KO) mice, MMP-2 KO mice, and double KOs. 24,55 When MMP-9 expression is induced in HUVECs, its activity can be increased with 1.3 to 8 μM H2O2 with minimal increase (1.2-fold) in MMP-9 mRNA. 24 An area for future research is to determine whether other adhesion molecules such as CD44 or PECAM-1, which do not activate ROS signals, 3,6 modulate MMPs, thus potentially providing a redundancy in signals that participate in activation of MMPs during migration.

Although the rapid VCAM-1–stimulated endothelial cell MMP activation is involved in VCAM-1–dependent lymphocyte migration, the delayed activation of lymphocyte MMPs is interesting and warrants some discussion of this delay. The ROS that activate lymphocyte MMPs are generated from the endothelial cells because pretreatment of the endothelial cells but not the lymphocytes with an irreversible inhibitor of flavoproteins, DPI, blocked VCAM-1 activation of lymphocyte MMPs. Because ROS are released by the endothelial cells at the endothelial cell surface with a bound lymphocyte, one might expect direct activation of lymphocyte-associated MMPs; however, our data and other reports indicate a delayed activation of lymphocyte MMPs after binding to VCAM-1 on endothelial cells. 3,5,41 In addition, exogenous ROS activated lymphocyte MMPs after 5 hours. This delay suggests that indirect signals are necessary for activation of lymphocyte MMPs. The 1 μM H2O2 generated by VCAM-1 stimulation is too low for H2O2 (>25 μM) activation of nuclear factor κB (NFκB)–induced MMP-9 mRNA in lymphocytes. 26 Consistent with this finding, lymphocyte MMP-9 protein expression was not increased by VCAM-1 stimulation or H2O2. Lymphocytes have relatively high levels of endogenous inhibitors of MMPs, TIMPs. 31,32 Indeed, 1 μM H2O2 reduced TIMP-1 and TIMP-2 expression in the resting splenic lymphocytes at 5 hours. Thus, a H2O2–induced increase in MMP/TIMP ratio mediates a net increase in MMP enzymatic activity. Thus, this report identifies a role for ROS in activation of lymphocyte MMPs.

In summary, this is the first report to demonstrate a function for endothelial cell MMPs after VCAM-1 binding. VCAM-1 signaling stimulates the release of low levels of H2O2 4 that result in endothelial cell MMP activation within minutes, and these endothelial cell MMPs are required for VCAM-1–dependent lymphocyte migration. Furthermore, the level of shear stress at postcapillary venules does not alter VCAM-1 activation of endothelial cell MMPs, and it has been reported that this level of shear stress does not alter endothelial cell generation of ROS. 37 Our data are consistent with the working model that MMPs associated with the endothelial cell are directly activated by low levels of extracellular ROS generated by NADPH oxidase in the endothelial cell membrane. MMPs secreted by the endothelial cells in vivo are likely flushed from the site by the flow of blood. MMPs are anchored to cell surfaces by transmembrane MMPs, CD44, and integrins. 23,33,36 The mHEVc cell line expresses CD44 42 and the transmembrane MT1-MMP. MT1-MMP retains activated MMP-2 as well as pro-MMP-2 at the plasma membrane, whereas CD44 can bind activated MMP-9. 23,36 By using a mechanism of MMP cell surface retention, localized ROS generation activates MMPs associated with the endothelial cell, likely at the site of lymphocyte binding, so that endothelial cells can retract only at the site of lymphocyte interaction. 14 At this site, endothelial cell–associated MMPs could degrade several endothelial cell surface molecules that form endothelial cell junctions such as extracellular matrix and adhesion molecules. 9,10 The rest of the endothelial cell maintains its cell shape and thus ensures that endothelium integrity remains relatively intact. This report contributes to our understanding of VCAM-1 signals and thus will aid in the design of modulators for VCAM-1–dependent functions in diseases such as asthma and EAE.

Acknowledgments

We thank Drs Amy Sang and Jeff Gidday for their suggestions. We also thank Jay Card for photographic assistance.

References

16. Yamamoto H, Sedgwick JB, Busse WW. Differen-
tial regulation of eosinophil adhesion and transmi-
19. Ager A, Misty S. Interaction between lympho-
cytes and cultured high endothelial cells: an in vitro model of lymphocyte migration across high


Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species

Tracy L. Deem and Joan M. Cook-Mills